KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EBITDA (2016 - 2025)

Biogen (BIIB) has 17 years of EBITDA data on record, last reported at $1.3 billion in Q4 2025.

  • For Q4 2025, EBITDA fell 6.85% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $3.5 billion, up 183.61%, while the annual FY2025 figure was $5.7 billion, 91.75% up from the prior year.
  • EBITDA reached $1.3 billion in Q4 2025 per BIIB's latest filing, up from -$117.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.4 billion in Q4 2024 and bottomed at -$800.8 million in Q3 2023.
  • Average EBITDA over 5 years is $472.9 million, with a median of $536.4 million recorded in 2021.
  • Peak YoY movement for EBITDA: tumbled 188.82% in 2023, then skyrocketed 1821.32% in 2025.
  • A 5-year view of EBITDA shows it stood at $587.1 million in 2021, then crashed by 94.4% to $32.9 million in 2022, then skyrocketed by 786.32% to $291.6 million in 2023, then surged by 366.77% to $1.4 billion in 2024, then decreased by 6.85% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $1.3 billion in Q4 2025, -$117.1 million in Q3 2025, and $1.1 billion in Q2 2025.